Bioxytran (OTCMKTS:BIXT) & Aerovate Therapeutics (NASDAQ:AVTE) Critical Analysis

Aerovate Therapeutics (NASDAQ:AVTE) and Bioxytran (OTCMKTS:BIXT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Profitability

This table compares Aerovate Therapeutics and Bioxytran’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Bioxytran	N/A	N/A	-2,106.99%

Earnings & Valuation

This table compares Aerovate Therapeutics and Bioxytran”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52 million	($2.99)	-0.81
Bioxytran	N/A	N/A	-$4.28 million	($0.01)	-8.75

Bioxytran is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Aerovate Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Bioxytran has a beta of -0.55, meaning that its share price is 155% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Aerovate Therapeutics and Bioxytran, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0	6	0	0	2.00
Bioxytran	0	0	0	0	0.00

Aerovate Therapeutics presently has a consensus target price of $2.25, suggesting a potential downside of 7.41%. Given Aerovate Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Aerovate Therapeutics is more favorable than Bioxytran.

Summary

Aerovate Therapeutics beats Bioxytran on 5 of the 8 factors compared between the two stocks.

About Aerovate Therapeutics

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

About Bioxytran

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.